



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of
Ho-Sik RHO, et al.

Docket No: Q93181

Appln. No.: 10/595,124

Group Art Unit: Unknown

Confirmation No.: 3044

Examiner: Unknown

Filed: February 27, 2006

For: HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING
THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. D. Zacheis, et al., "Heteroarotinoids Inhibit Head and Neck Cancer Cell Lines in Vitro and in Vivo Through Both TAT and RXR Retinoic Acid Receptors", *J. Med. Chem.*, **1999**, 42, 4434-4445.
2. H. Kagechika, et al., "Retinobenzoic Acids. 1. Structure-Activity Relationships of Aromatic Amides with Retinoidal Activity", *J. Med. Chem.*, **1988**, 31, 2182-2192.
3. E. Schwartz, et al., "Topical All-Trans Retinoic Acid Stimulates Collagen Synthesis In Vivo", *The Journal of Investigative Dermatology*, Vol. 96, No. 6, June 1991, pp. 975-978.
4. S. Kang, "Photoaging and Tretinoin", *Dermatologic Clinics*, Vol. 16, No. 2, April 1998, pp. 357-364.

Ho-Sik RHO, et al.
INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/595,124

5. M. Ebisawa et al., "Novel Retinoidal Tropolone Derivatives. Bioisosteric Relationship of Tropolone Ring with Benzoic Acid Moiety in Retinoid Structure", *Chem. Pharm. Bull.*, Vol. 49, No. 4, 2001, pp. 501-503.


One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Sunhee Lee
Registration No. 53,892


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 15, 2006

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			<i>Complete if Known</i>	
			Application Number	10/595,124
			Confirmation Number	3044
			Filing Date	February 27, 2006
			First Named Inventor	Ho-Sik RHO
			Art Unit	Unknown
			Examiner Name	Unknown
Sheet	1	of	Attorney Docket Number	Q93181

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ <i>(if known)</i>			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		D. Zacheis, et al., "Heteroarotinoids Inhibit Head and Neck Cancer Cell Lines in Vitro and in Vivo Through Both TAT and RXR Retinoic Acid Receptors", <i>J. Med. Chem.</i> , 1999 , 42, 4434-4445	
		H. Kagechika, et al., "Retinobenzoic Acids. 1. Structure-Activity Relationships of Aromatic Amides with Retinoidal Activity", <i>J. Med. Chem.</i> , 1988 , 31, 2182-2192	
		E. Schwartz, et al., "Topical All-Trans Retinoic Acid Stimulates Collagen Synthesis In Vivo", <i>The Journal of Investigative Dermatology</i> , Vol. 96, No. 6, June 1991, pp. 975-978	
		S. Kang, "Photoaging and Tretinoin", <i>Dermatologic Clinics</i> , Vol. 16, No. 2, April 1998, pp. 357-364	
		M. Ebisawa et al., "Novel Retinoidal Tropolone Derivatives. Bioisosteric Relationship of Tropolone Ring with Benzoic Acid Moiety in Retinoid Structure", <i>Chem. Pharm. Bull.</i> , Vol. 49, No. 4, 2001, pp. 501-503	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.